Serum Soluble Fas Levels and Incidence of Liver Cancer in Nested Case-Control Study
Serum Soluble Fas Levels and Incidence of Liver Cancer in Nested Case-Control Study
复制标题
DOI：
10.1158/1055-9965.epi-22-0902
复制
发表时间：
2023-02-01
影响因子：
3.8
通讯作者：
Tamakoshi，Akiko
中科院分区：
文献类型：
--
作者：
Adachi，Yasush;Nojima，Masanori;Tamakoshi，Akiko
背景可溶性Fas（sFas）通过与Fas配体结合抑制细胞凋亡，在肿瘤的发生和肿瘤的播散中发挥多种作用。我们分析了血清sFas水平与肝癌的发病率在一个前瞻性的病例对照研究嵌套在日本协作队列Study.MethodsA基线调查进行了从1988年，从39,242例受试者的血液样本。以确诊为肝癌的患者为例。选择两个或三个对照组，并按性别、年龄和地理区域进行匹配。条件Logistic回归被用来估计OR与sFas.ResultsThis研究包含86例和249对照组的癌症发病率。在控制酒精摄入、体重指数、吸烟和肝炎病毒感染后，高sFas参与者显示癌症风险升高（Ptrend= 0.003），与第一个三分位数相比，第三个三分位数的sFas显示出更高的风险[OR，3.53; 95%置信区间（CI），1.28-9.69]。在肝细胞癌中，高sFas与高风险相关（P趋势< 0.001）。在男性和老年人中，最高三分位数的受试者显示出更高的癌症风险。仅限于随访3年的受试者，高sFas与肝癌风险相关（P趋势= 0.033），第三个三分位数与第一个三分位数相比，（OR，2.94; 95%可信区间，结论高血清sFas可能与肝癌的未来风险有关。更大的前瞻性队列。
BackgroundSoluble Fas (sFas) plays various roles in carcinogenesis and tumor dissemination by preventing apoptosis via binding to Fas ligand. We analyzed associations of serum sFas levels with the incidence of liver cancer in a prospective case–control study nested in the Japan Collaborative Cohort Study.MethodsA baseline survey was conducted from 1988, with blood samples obtained from 39,242 subjects. Patients diagnosed with liver cancer were regarded as cases. Two or three controls were selected and matched for sex, age, and geographic area. Conditional logistic regression was used to estimate ORs for cancer incidence associated with sFas.ResultsThis study contained 86 cases and 249 controls. After controlling for alcohol intake, body mass index, smoking, and hepatitis viral infection, participants with high sFas showed elevated risk of cancer (Ptrend= 0.003) and the third tertile of sFas showed a higher risk compared with the first tertile [OR, 3.53; 95% confidence interval (CI), 1.28–9.69]. In hepatocellular carcinoma, high sFas was associated with elevated risk (Ptrend< 0.001). In men and the elderly, subjects in the highest tertiles showed higher cancer risk. Limiting subjects to those followed for 3 years, high sFas was related to liver cancer risk (Ptrend= 0.033) and the third tertile showed a higher risk compared with the first (OR, 2.94; 95% CI, 0.94–9.14).ConclusionsHigh serum sFas may be related to future risk of liver cancer.ImpactOur findings highlight this biomarker for further analysis in pooled investigations with different/larger prospective cohorts.